Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENCE (Canaglifl...

Full description

Saved in:
Bibliographic Details
Published in:Circulation
Main Authors: Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Capuano, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Sun, Tao, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Brenner, Barry M., Perkovic, Vlado
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2019
Subjects:
Original Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727954/
https://ncbi.nlm.nih.gov/pubmed/31291786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items